Beauvericin induces cytotoxic effects in human acute lymphoblastic leukemia cells through cytochrome c release, caspase 3 activation: the causative role of calcium

Cancer Lett. 2004 Dec 28;216(2):165-73. doi: 10.1016/j.canlet.2004.06.005.

Abstract

Beauvericin (BEA), a cyclic hexadepsipeptide, induces cell death in human leukemia cells (CCRF-CEM) and the process of BEA-induced cell death has been speculated to undergo an apoptotic pathway. In the present study, several well-characterized factors, known to play important roles in apoptotic pathway, were investigated in BEA-induced CCRF-CEM cell death. CCRF-CEM cells were treated with BEA at concentrations from 1 to 10 microM for up to 24 h. The incidence of nuclear fragmentation and apoptotic body formation in the cells, cytosolic caspase-3 activity, mitochondrial membrane potential, and release of cytochrome c (Cyt c) from mitochondria in BEA-treated cells were determined and compared with that in untreated cells. Moreover, to investigate the role of intracellular Ca++ in this cell death process, CCRF-CEM cells were primed with 3 microM of BAPTA/AM, a Ca++ chelator, to exclude intracellular Ca++ prior to the BEA treatment. The data revealed that BEA-induced cell death in CCRF-CEM cells exhibited a dose- and time-dependent manner. The incidence of nuclear fragmentation and apoptotic body formation was significantly increased in CCRF-CEM cells treated with BEA at concentrations of 1 microM or greater. Increase of cytosolic caspase-3 activity was also observed in BEA-treated cells with a dose-dependent manner. In addition, increased release of Cyt c from mitochondria was also observed in the cells treated with 10 microM BEA in a time-dependent pattern. The BAPTA/AM pretreatment partially blocked BEA-induced cell death in CCRF-CEM cells, indicating that intracellular Ca++ plays an important role, maybe as a mediator in cell death signaling, in this cell death pathway. The results support the notion that BEA-induced cell death in CCRF-CEM cells likely undergo through an apoptotic pathway on the basis of increase of release of Cyt c from mitochondria, increase of caspase-3 activity, and some observed typical apoptotic cellular changes in morphology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis*
  • Calcium / metabolism*
  • Caspase 3
  • Caspases / metabolism
  • Cell Death
  • Cell Line, Tumor
  • Chelating Agents / pharmacology
  • Cytochromes c / metabolism
  • Cytosol / metabolism
  • Depsipeptides / pharmacology*
  • Dose-Response Relationship, Drug
  • Egtazic Acid / analogs & derivatives*
  • Egtazic Acid / pharmacology
  • Humans
  • Morpholines / pharmacology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma

Substances

  • Chelating Agents
  • Depsipeptides
  • Morpholines
  • 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester
  • beauvericin
  • Egtazic Acid
  • lateritin
  • Cytochromes c
  • CASP3 protein, human
  • Caspase 3
  • Caspases
  • Calcium